Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
dominant-negative Mastermind-like 1 viral vector
- Development stage
- Preclinical
- Lead developer
- University of Miami
- Modality
- Gene Therapies
- Administration
- Intratumoral
01
Overview
Dominant-negative Mastermind-like 1 (DN-MAML1) viral vector is a gene therapy tool designed to inhibit the Notch signaling pathway. Mastermind-like 1 (MAML1) is a critical co-activator that binds to the Notch intracellular domain (NICD) and CSL (CBF1/RBP-Jκ) to form a transcriptional activation complex. The dominant-negative form of MAML1 typically consists of the N-terminal Notch-binding domain but lacks the transactivation domains; it competitively binds to the NICD/CSL complex, thereby preventing the recruitment of other co-activators and effectively blocking Notch-mediated gene transcription. In oncology research, particularly in melanoma, this vector is used to study the role of Notch signaling in tumor progression, cell growth, and survival by antagonizing the oncogenic effects of aberrant Notch activation.
- Other names
- DN-MAML1 viral vectorDN-MAML-1 viral vectorDN-MAML 1 viral vectordominant-negative MAML1dominant-negative Mastermind-like 1
02
Targets
Nuclear factor kappa B RelA-containing transcriptional complexNOTCH (Neurogenic locus notch homolog protein 3)
Beyond the preview
Go deeper on dominant-negative Mastermind-like 1 viral vector.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on dominant-negative Mastermind-like 1 viral vector.